Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
The European Respiratory Journal
|
September 29, 2012
Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study
Robert Wilson, Tobias Welte, Eva Polverino, et al.
The Journal of Antimicrobial Chemotherapy
|
September 8, 2011
A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections
Inge C Gyssens, Matthew Dryden, Peter Kujath, et al.
Antimicrobial Agents and Chemotherapy
|
April 17, 2019
Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection
Xiaoju Lv, Jeff Alder, Li Li, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 1, 2008
Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia
Peter E Pertel, Patricia Bernardo, Charles Fogarty, et al.
Journal of Clinical Microbiology
|
July 11, 2008
Clinical rationale for treatment of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin
Zukile Gqada, Ben Marais, Elizabeth Wasserman, et al.
The Lancet. Infectious Diseases
|
January 22, 2013
A comprehensive regulatory framework to address the unmet need for new antibacterial treatments
John H Rex, Barry I Eisenstein, Jeff Alder, et al.
The Lancet. Infectious Diseases
|
September 28, 2013
Addressing the need for new antibacterials--authors' reply
John H Rex, Barry I Eisenstein, Jeff Alder, et al.
The Lancet. Infectious Diseases
|
December 24, 2019
Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial
Michael S Niederman, Jeff Alder, Matteo Bassetti, et al.
Journal of Clinical Microbiology
|
July 4, 2008
Associations between the genotypes of Staphylococcus aureus bloodstream isolates and clinical characteristics and outcomes of bacteremic patients
Tahaniyat Lalani, Jerome J Federspiel, Helen W Boucher, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 2, 2016
New Antimicrobial Agents … but No Susceptibility Tests!
Jane E Ambler, Kevin M Krause, Judith N Steenbergen, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
The European Respiratory Journal
|
September 29, 2012
Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study
Robert Wilson, Tobias Welte, Eva Polverino, et al.
The Journal of Antimicrobial Chemotherapy
|
September 8, 2011
A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections
Inge C Gyssens, Matthew Dryden, Peter Kujath, et al.
Antimicrobial Agents and Chemotherapy
|
April 17, 2019
Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection
Xiaoju Lv, Jeff Alder, Li Li, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 1, 2008
Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia
Peter E Pertel, Patricia Bernardo, Charles Fogarty, et al.
Journal of Clinical Microbiology
|
July 11, 2008
Clinical rationale for treatment of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin
Zukile Gqada, Ben Marais, Elizabeth Wasserman, et al.
The Lancet. Infectious Diseases
|
January 22, 2013
A comprehensive regulatory framework to address the unmet need for new antibacterial treatments
John H Rex, Barry I Eisenstein, Jeff Alder, et al.
The Lancet. Infectious Diseases
|
September 28, 2013
Addressing the need for new antibacterials--authors' reply
John H Rex, Barry I Eisenstein, Jeff Alder, et al.
The Lancet. Infectious Diseases
|
December 24, 2019
Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial
Michael S Niederman, Jeff Alder, Matteo Bassetti, et al.
Journal of Clinical Microbiology
|
July 4, 2008
Associations between the genotypes of Staphylococcus aureus bloodstream isolates and clinical characteristics and outcomes of bacteremic patients
Tahaniyat Lalani, Jerome J Federspiel, Helen W Boucher, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 2, 2016
New Antimicrobial Agents … but No Susceptibility Tests!
Jane E Ambler, Kevin M Krause, Judith N Steenbergen, et al.
Page
of 3